WallStSmart
KALA

Kala Pharmaceuticals Inc

NASDAQ: KALA · HEALTHCARE · BIOTECHNOLOGY

$3.09
-6.28% today

Updated 2026-06-03

Market cap
$45.17M
P/E ratio
P/S ratio
23.75x
EPS (TTM)
$-102.01
Dividend yield
52W range
$2 – $1,030
Volume
2.4M

Kala Pharmaceuticals Inc (KALA) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item2013201420152016201720182019202020212022202320242025
Total assets$7.07M$11.72M$8.45M$46.33M$116.13M$220.97M$154.32M$221.61M$139.43M$86.82M$55.95M$55.48M$9.49M
Cash & equivalents$5.34M$10.62M$5.76M$45.47M$114.56M$170.90M$85.45M$77.26M$92.14M$70.50M$50.90M$51.18M$7.56M
Current assets$5.97M$10.78M$5.87M$45.63M$115.21M$177.03M$105.48M$171.38M$124.37M$85.94M$52.87M$52.80M$9.49M
Total liabilities$6.87M$8.46M$14.24M$134.09M$26.45M$115.98M$124.63M$121.61M$122.62M$67.85M$48.45M$43.15M$2.49M
Current liabilities$5.58M$2.95M$5.51M$5.55M$14.46M$17.01M$24.77M$22.23M$37.42M$25.68M$8.35M$16.96M$2.49M
Long-term debt$4.66M$7.79M$9.10M$11.99M$70.23M$71.18M$72.24M$78.93M$37.94M$34.19M$20.10M
Shareholder equity$202000.00$3.26M$-5.79M$-87.76M$89.68M$104.99M$29.69M$100.00M$16.80M$18.97M$7.50M$12.33M$7.00M
Retained earnings$-22.93M$-42.29M$-58.97M$-92.14M$-134.37M$-201.11M$-295.46M$-399.78M$-542.39M$-587.21M$-629.41M$-667.92M$-694.90M
Accounts receivable$303000.00$38000.00$1.03M$13.10M$9.85M$17.45M$6.50M$236000.00
Inventory$0.00$4.09M$4.65M$5.23M$8.64M$7.67M
Goodwill$0.00

Frequently asked questions

How much free cash flow does KALA generate?

KALA produced $-32.01M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is KALA's balance sheet healthy?

KALA holds $7.56M in cash and equivalents against — in long-term debt, on $7.00M of shareholder equity. That debt is best read against the cash flow the business throws off each year.